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CD8 T-cell responses were examined in subjects with incident (new following negative visits) or prevalent (lasting ≥ 4m o n t h s )
human papillomavirus type 16 (HPV16) or human papillomavirus (HPV18) infection. The groups were chosen from a cohort
of women being followed every 4 months with cervical cytology and HPV-DNA testing. Enzyme-linked immunospot (ELISPOT)
assay was performed at enrollment (time zero) and one year later. At time zero, 1 (6%) of 17 subjects with incident HPV 16/18
infections had positive ELISPOT results which increased to 6 (35%) at one year. For the subjects with prevalent HPV 16/18
infections, the ELISPOT results were similar at time zero (2 (15%) of 15 subjects positive) and at one year (3 (20%)). While
all of the 11 women with prevalent HPV16 infection showed clearance one year later, unexpectedly only 1 (25%) of 4 women with
prevalent HPV18 infection demonstrated clearance one year later (P = .009).
1.Introduction
A majority of human papillomavirus (HPV) infections
is cleared within a few years [1, 2]. However, persistent
infectionsofthecervixbyhigh-riskHPVtypesareassociated
with the development of cervical cancer [3, 4]. In patients
infected with human immunodeﬁciency virus (HIV), the
nature of T-cell immune responses in primary infections was
shown to be important in viral control and were found to be
quite diﬀerent from that in chronic infections [5]. In order
to compare the nature of immune responses between short-
term and long-lasting HPV infections, we examined T-cell
responses in subjects with incident (new infection detected
following HPV negative visits) and prevalent (lasting ≥ 4
months) human papillomavirus type 16 (HPV16) or human
papillomavirustype18(HPV18)infection.Thesubjectswere
recruited from a long-term study of the natural history of
HPV infection.
2. Methods
2.1. Subjects. The parent study enrolled young women aged
13–21 years with sexual experience of less than 5 years [6].
Interview, cervical cytology, and HPV-DNA testing using
cervical lavage specimen were performed every 4 months.
For the current study, two groups were chosen: (1) women
with an incident HPV16 or HPV18 infection (undetectable
HPV-DNA results for two consecutive visits followed by a
positive one) and (2) women with a prevalent HPV16 or 18
infection (those with at least two consecutive visits positive
for HPV16 or HPV18) (Figure 1). The HPV-DNA testing
results one year later were then used to determine whether
the incident or prevalent infection was still detectable. In
addition, 20 subjects who never had HPV16 and HPV18
detected were enrolled as negative controls. Approvals were
obtained from the Committee on Human Research of the
University of California at San Francisco and from the2 ISRN Obstetrics and Gynecology
0
a
b
c
d
Elispot Elispot
−8 −41 2
(month)
Figure 1: Natural history of HPV16 or HPV18 infection and time
points at which ELISPOT assays were performed. (a) Schematic
representation of an incident HPV16 or HPV18 infection which
cleared one year later. (b) Schematic representation of an incident
HPV16 or HPV18 infection which persisted one year later. (c)
SchematicrepresentationofaprevalentHPV16orHPV18infection
which lasted at least four months at the time of study entry and
which cleared one year later. (d) Schematic representation of a
prevalent HPV16 or HPV18 infection which lasted at least four
monthsatthetimeofstudyentryandwhichpersistedoneyearlater.
“”: a visit at which HPV16 or HPV18 DNA was detected. “”: a
visit at which HPV-DNA testing result was negative for HPV16 and
HPV18.
Institutional Review Board of the University of Arkansas for
Medical Sciences, and informed consent was obtained from
each subject.
2.2. HPV-DNA Testing. The cervicovaginal lavage samples
were tested using the PGMY09/11 primer system as previ-
ously described [6]. The PCR ampliﬁed product was tested
with a reverse line blot assay (Roche Molecular Diagnostics,
Inc., Alameda, CA) for the presence of a positive β-globin
signal (indicating sample adequacy) and for the following
HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 57, 58, 59, 66, 68, 73, 82, 83, and 84.
2.3. Cloning and Expression of HPV18 E6 and E7 Proteins.
Recombinant vaccinia viruses expressing HPV18 E6 and
E7 separately, used to establish CD8 T-cell lines, were
constructed in the same manner as the HPV16 E6-vac and
E7-vac [7]. The E6 and E7 genes were PCR-ampliﬁed from
a plasmid containing HPV18 [8] using primers designed
to insert Kpn I and Sal I restriction enzyme sites. The
ampliﬁed and digested DNA fragments were ligated into
pSC65 [9]. The resultant plasmid transfer vectors contained
inserted open reading frames regulated by a strong synthetic
early/late vaccinia promoter and the lacZ gene regulated
by the P7.5 early/late vaccinia virus promoter ﬂanked by
vaccinia virus thymidine kinase gene. The E6 and E7 genes
from the plasmid transfer vectors were sequenced, and the
results matched with the sequences from the GenBank. Cells
were infected with the WR wild-type vaccinia virus strain
and transfected with the plasmid transfer vector containing
the E6 or E7 gene. The recombinants (HPV18 E6-vac E7-
vac, resp.) were isolated by TK selection, and plaques were
puriﬁed. CV-1 cells were infected with HPV18 E6-vac or E7-
vac, and cell lysates were resolved on a SDS-PAGE gel, which
wastransferredtoaZeta-Probeblottingmembrane(Bio-Rad
Laboratories, Hercules, CA). The expression of the HPV18
E6 or E7 protein was conﬁrmed by Western blotting per-
formed using HPV 16/18 E6-speciﬁc monoclonal antibody
(C1P5, Chemicon International, Temecula, CA) or HPV18
E7-speciﬁc antibody (718-15, Abcam Inc., Cambridge, MA).
2.4. Enzyme-Linked Immunospot (ELISPOT) Assay. Blood
samples to establish HPV16- or HPV18-speciﬁc CD8 T-
cell lines and to perform interferon-γ ELISPOT assay [10,
11] were drawn as soon as incident or prevalent infection
was known. A second blood draw was performed one
year later. Peripheral blood mononuclear cells (separated
magnetically into CD14-positive cells and CD14-negative
cells) were cryopreserved, and both samples were analyzed
simultaneously. The HPV16-based ELISPOT assay for E6
and E7 proteins was performed for subjects with HPV16
infection as previously described [11], and the same was
done for HPV18. The E6 protein was tested using 10 pools
of 3 overlapping synthetic 15-mer peptides for HPV16 [11]
and for HPV18. Six pools of three 15-mer synthetic peptides
were used to cover the HPV16 E7 protein, while six pools
and an additional peptide, HPV18 E7 (91–105), were tested
for the HPV18 E7 protein. CD8 T-cell line was established,
and ELISPOT assay was performed once for the 20 negative
control subjects: 10 subjects were tested with the HPV16-
based assay, and the other 10 subjects were tested with the
HPV18-based assay.
2.5. Statistical Analysis. Statistical analyses were performed
using GraphPad Software (GraphPad Software Inc., La Jolla,
CA). Fisher’s exact test (two tailed) was used to make
comparisons between 2 groups, and unpaired t-test was
used to compare the duration of persistence prior to entry
between the HPV16 and HPV18 prevalent groups. A P value
of less than .05 was considered to be signiﬁcant.
3. Results
The mean age of subjects at enrollment for this substudy was
23.4years.Theﬁrstbloodsamplesweredrawnwithinamean
of 77 ± 40 days after the incident and prevalent infections
wereknown.Attimezero,1(6%)of17subjectswithincident
HPV 16/18 infections had positive ELISPOT results which
increased to 6 (35%) at 1 year (P = .09). After one year, 12
(71%) of 17 subjects with an incident HPV 16/18 infections
showedclearance(Table 1).However,therewasnodiﬀerence
in ELISPOT results between the subjects whose HPV 16/18
infections cleared (4 of 12 or 33%) versus persisted (2 of 5 or
40%, P = 1) at one year point.ISRN Obstetrics and Gynecology 3
Table 1: Course of HPV infections.
HPV Type HPV16 HPV18
One Year Later Cleared, no (%) Still Present, no (%) Cleared, no (%) Still Present, no (%)
Incident 9 (75) 3 (25) 3 (60) 2 (40)
Prevalent 11 (100) 0 (0) 1 (25) 3 (75)
For the subjects with prevalent infection, the mean
duration of persistence prior to enrollment in this substudy
was 513±139 days for the HPV16 group and 916±208 days
for the HPV18 group (P = .1). At time zero, 2 (15%) of 15
subjects with prevalent HPV 16/18 infections had positive
ELISPOT results while 3 (20%) of them did at 1 year (P =
1). Three (25%) of 12 subjects whose prevalent HPV 16/18
infections cleared had positive ELISPOT results while none
(0%) of 3 subjects whose infections persisted (P = 1) at one
year.Interestingly,allofthe11womenwithprevalentHPV16
infection showed clearance one year later. In comparison,
only 1 (25%) of 4 women with prevalent HPV18 infection
demonstrated clearance one year later (P = .009) (Table 1).
The rate of positive CD8 T-cell responses was 27% (3 of 11)
amongthosewithprevalentHPV16infectionsand0%(none
of 4) among those with prevalent HPV18 infections one year
later (P = .5).
None of the negative control subjects had any positive
ELISPOT results. There was a signiﬁcant diﬀerence between
the ELISPOT results of the negative control group and the
ELISPOT results at one year after the incident HPV 16/18
infections (6 (35%) of 17 women had positive ELISPOT
results (P = .005)).
4. Discussion
The CD8 T-cell immune responses mount more frequently
after incident HPV 16/18 infections (6% to 35%) compared
to prevalent HPV 16/18 infections (15% to 20%). However,
only a statistical trend was demonstrated due to small num-
ber of subjects. These results are quite diﬀerent from those
examining HIV-positive subjects in which robust systemic
CD8 T-cell responses were demonstrated during primary
and chronic infections although their roles in controlling
HIV infections were distinct [5]. The presence of robust
systemic immunity in HIV compared to HPV infections may
be due to the fact that HIV causes systemic infections while
HPV causes localized infections such as in cervix.
A surprising ﬁnding was that persistence one year later
was more common for HPV18 compared to HPV16 among
those women who were found to have prevalent infection
at enrollment. There seems to be an immunological basis
for the diﬀerence (27% for HPV16 versus 0% for HPV18
at 1 year), but it was not statistically signiﬁcant unlike
the ﬁndings in other studies for which we performed the
same assay [10, 11]. This was likely due to the small
number of subjects in this study. The ﬁnding that the
prevalent HPV18 infection persisted more often than the
prevalent HPV16 infection was unexpected given that other
investigators have reported HPV16 to be the type that most
commonly persisted [12, 13] although the time periods
observed were much longer in these studies (5 years and
5–7 years, resp.). Although the duration of persistence for
the HPV18 prevalent group was longer than that for the
HPV16 prevalent group, this diﬀerence was not statistically
signiﬁcant. While a longer duration of persistence is thought
to lead to further persistence [14], this diﬀerence alone did
not seem to explain the signiﬁcant diﬀerence in the HPV
persistence 1 year later between the HPV16 and HPV18
prevalent groups in this study. HPV18 infection is associated
with glandular lesions that are often diﬃcult to detect by
cytology [15]. Therefore, it is tempting to speculate that
HPV18 infection may take a diﬀerent course compared
to other high-risk HPV types. Indeed, 4 of 9 cases of
cervical cancer diagnosed at the 2nd observations were
associated with HPV18 in the study reported by Schiﬀman
and colleagues [13]. Findings from another study suggested
that HPV18 may be more oncopotent in some population
than HPV16 although the latter was more prevalent [16].
The weakness of this study was the small number of subjects
enrolled; however, it is extremely diﬃcult to accumulate
suﬃcient number of subjects with a well-characterized
historyofHPV16orHPV18infection.Nevertheless,itwould
be important to corroborate the ﬁndings of this study.
5. Conclusion
A trend indicating the CD8 T-cell immune responses
mount more frequently after incident HPV 16/18 infections
compared to prevalent HPV 16/18 infections was described,
but an analysis of a larger number of subjects is warranted.
Unexpectedly, HPV18 was detected signiﬁcantly more fre-
quently than HPV16 one year following prevalent infection.
Whether this was due to less CD8 T-cell responses mounted
against HPV18 compared to HPV16 was not clear.
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